NANTONG,
KuTai (Cisatracurium Besylate), on the market since 2006, had not been
covered by any medical insurance before the Chinese government granted
approval for its inclusion on the list of insured drugs on
Typically, the Chinese government observes the performance of new
generation drugs in the market for several years to ensure their safety and
efficacy profile is well established before considering them for inclusion on
the list of insured pharmaceuticals. Following Sinobiopharma's launch of this
latest generation of muscle relaxant in
"We are very pleased that KuTai has finally been approved for insurance
coverage," said Dr.
About Sinobiopharma
Sinobiopharma, Inc. is a fully integrated and highly innovative specialty
biopharmaceutical company engaged in the research and development, manufacture
and marketing of biopharmaceutical products in
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.
For more information, please contact: Sinobiopharma, Inc. Investor Relations Tel: +1-203-987-5632
SOURCE Sinobiopharma, Inc.